Developability of Biotherapeutics
portes grátis
Developability of Biotherapeutics
Computational Approaches
Kumar Singh, Satish; Kumar, Sandeep
Taylor & Francis Ltd
06/2021
316
Mole
Inglês
9781032098203
15 a 20 dias
585
Descrição não disponível.
PRINCIPLES OF BIOPHARMACEUTICAL INFORMATICS. Biopharmaceutical Informatics: Applications of Computation in Biologic Drug Development. Computational Methods in the Optimization of Biologic Modalities. Understanding, Predicting, and Mitigating the Impact of Posttranslational Physiochemical Modifications, Including Aggregation, on the Stability of Biopharmaceutical Drug Products. Preclinical Immunogenicity Risk Assessment of Biotherapeutics. Application of Mechanistic Pharmacokinetic-Pharmacodynamic Modeling toward the Development of Biologics. Challenges in High-Concentration Biopharmaceutical Drug Delivery: A Modeling Perspective. DEVELOPABILITY PRACTICES IN THE BIOPHARMACEUTICAL INDUSTRY. Best Practices in Assessment of Developability of Biopharmaceutical Candidates. Best Practices in Developability Assessments of Therapeutic Protein Candidates in the Biopharmaceutical Industry. Best Practices in Assessing the Developability of Biopharmaceutical Candidates. Developability Assessment Workflows to De-Risk Biopharmaceutical Development.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Developability Assessment;T-cell Epitopes;Aggregation Prone Regions;Aggregation Propensity;Met Oxidation;Asn Deamidation;Immunogenicity Risk;Biologic Drug;TMDD Model;Ph Ar;CG Model;Ich Q8;CG Site;ADME Property;Clo Ne;PDB Entry;mAb1 Solutions;Physicochemical Degradation;MHC Class Ii;CG Simulation;Signal Peptide;Risk Assessment;Potential T-cell Epitopes;Elastic Network Model;Data Set
PRINCIPLES OF BIOPHARMACEUTICAL INFORMATICS. Biopharmaceutical Informatics: Applications of Computation in Biologic Drug Development. Computational Methods in the Optimization of Biologic Modalities. Understanding, Predicting, and Mitigating the Impact of Posttranslational Physiochemical Modifications, Including Aggregation, on the Stability of Biopharmaceutical Drug Products. Preclinical Immunogenicity Risk Assessment of Biotherapeutics. Application of Mechanistic Pharmacokinetic-Pharmacodynamic Modeling toward the Development of Biologics. Challenges in High-Concentration Biopharmaceutical Drug Delivery: A Modeling Perspective. DEVELOPABILITY PRACTICES IN THE BIOPHARMACEUTICAL INDUSTRY. Best Practices in Assessment of Developability of Biopharmaceutical Candidates. Best Practices in Developability Assessments of Therapeutic Protein Candidates in the Biopharmaceutical Industry. Best Practices in Assessing the Developability of Biopharmaceutical Candidates. Developability Assessment Workflows to De-Risk Biopharmaceutical Development.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Developability Assessment;T-cell Epitopes;Aggregation Prone Regions;Aggregation Propensity;Met Oxidation;Asn Deamidation;Immunogenicity Risk;Biologic Drug;TMDD Model;Ph Ar;CG Model;Ich Q8;CG Site;ADME Property;Clo Ne;PDB Entry;mAb1 Solutions;Physicochemical Degradation;MHC Class Ii;CG Simulation;Signal Peptide;Risk Assessment;Potential T-cell Epitopes;Elastic Network Model;Data Set
